Glucocorticoid Receptor Antagonist for Cushing's Differential Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentially diagnosing Cushing's Disease and Ectopic Cushing's Syndrome are invasive, costly, and prone to false negatives, requiring complex procedures like inferior petrosal venous sinus sampling and involving expensive agents like CRH and metyrapone, which are not readily available in the US.
Innovation Solution
A method involving the administration of a glucocorticoid receptor antagonist (GRA) to alter ACTH and cortisol production, with baseline and post-treatment cortisol and ACTH levels measured to calculate ratios, facilitating a differential diagnosis between Cushing's Disease and Ectopic Cushing's Syndrome based on changes in these ratios.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If inferior petrosal venous sinus sampling (IPSS) is used to diagnose Cushing's Disease, then diagnostic accuracy is improved, but patient risk and procedural complexity increase due to invasive catheterization
Solution Approach 1:
The patent uses a glucocorticoid receptor antagonist (GRA) as an intermediary substance to indirectly assess ACTH secretion patterns. Instead of directly sampling pituitary venous blood, the GRA blocks cortisol feedback to the pituitary, causing ACTH to rise in Cushing's Disease but remain suppressed in Ectopic Cushing's Syndrome. This mediator approach achieves diagnostic differentiation without invasive procedures
Solution Approach 2:
The patent replaces the mechanical invasive sampling system (catheterization of inferior petrosal sinus) with a biochemical testing system. By administering GRA and measuring ACTH response in peripheral blood, the method substitutes complex mechanical intervention with simple pharmacological challenge and blood analysis, eliminating catheterization risks while maintaining diagnostic capability
2Measurement precision
If inferior petrosal venous sinus sampling (IPSS) is used to diagnose Cushing's Disease, then diagnostic capability is improved, but device complexity and operational difficulty increase due to requirement for interventional radiologist
Solution Approach 1:
The GRA serves as a biochemical intermediary that simplifies the diagnostic process. Instead of requiring complex catheterization equipment and interventional radiology procedures, the method uses oral or IV administration of GRA followed by standard ACTH measurement in peripheral blood, making the test accessible in routine endocrinology clinics
Solution Approach 2:
The patent extracts the essential diagnostic information (ACTH secretion pattern) from the complex IPSS procedure. By using GRA to stimulate ACTH release and measuring it in easily accessible peripheral blood, the method separates the critical diagnostic signal from the invasive procedural complexity, achieving the same diagnostic goal with minimal intervention
3Loss of information
If CRH or metyrapone is used in diagnostic procedures, then diagnostic information is improved, but cost and availability worsen due to expense and limited availability in the US
Solution Approach 1:
The patent employs a glucocorticoid receptor antagonist (GRA) as a cost-effective alternative to expensive agents like CRH and metyrapone. GRA can be administered orally or intravenously with standard monitoring, eliminating the need for costly specialized reagents and complex laboratory infrastructure required for CRH stimulation or metyrapone suppression tests
Solution Approach 2:
The patent changes the diagnostic approach from using expensive exogenous hormones (CRH, metyrapone) to using a glucocorticoid receptor antagonist that works through a different mechanism. By blocking cortisol feedback rather than stimulating CRH release or inhibiting 11β-hydroxylase, the method achieves diagnostic information through a more economically viable pathway with readily available medications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a more accurate, convenient, and cost-effective means of diagnosis, eliminating the need for invasive procedures and allowing for precise differentiation between the two conditions through changes in cortisol to ACTH ratios post-GRA treatment.
Implementation Method 1
administering a glucocorticoid receptor antagonist (GRA) to alter ACTH and cortisol production
Data Source
AI summary
Improved methods and systems for diagnosing and for treating Cushing's syndrome and Cushing's Disease are provided herein, including methods and systems for concurrently treating Cushing's syndrome and differentially diagnosing Cushing's Disease from Ectopic Cushing's Syndrome in a patient with an established diagnosis of ACTH-dependent Cushing's syndrome. Treatment methods can use glucocorticoid receptor antagonists (GRAs), which differentially affect the ratio of cortisol to ACTH levels in patients having Cushing's Disease versus patients having Ectopic Cushing's Syndrome. Methods for concurrently treating and differentially diagnosing Cushing's Disease from Ectopic Cushing's Syndrome include obtaining baseline cortisol and ACTH levels of a patient, treating the patient with a GRA according to a protocol that would typically substantially elevate cortisol levels, obtaining post-treatment cortisol and ACTH levels of the patient, determining a differential relationship between baseline cortisol and ACTH levels and post-treatment cortisol and ACTH levels and providing a positive diagnosis based on the differential relationship.